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A B S T R A C T
Breast, ovarian and uterine cancers are the most common neoplasms among women. Several mechanisms may be
involved in oncogenesis and these include environmental and genetic factors. Bacteria may affect the devel-
opment of some cancers, with bacterial components, their products and metabolites interacting with susceptible
tissues. Commensalism and dysbiosis are important potential mechanisms involved in oncogenesis, and an ef-
fective strategy for diagnosis and treatment is required. The purpose of this review was to analyze the complex
associations between these cancers in women, and the microbiota, specifically bacterial microbes. However,
several cancers have an increased prevalence among individuals with HIV and HPV so the relationship between
viral infections and malignancies in women is also referred to. We described how different phylum of bacteria,
particularly in the gut, mammary tissue and vaginal microbiome may be involved in carcinogenesis; and we
discuss the potential pathways involved: (I), that lead to cell proliferation, (II), immune system perturbation,
(III), cell metabolic changes (e.g., hormonal factors), and (IV), DNA damage. Studies investigating the differ-
ences between the composition of the bacterial microbiota of healthy women compared to that present in various
conditions, and the clinical trials are summarized for the few studies that have addressed the microbiota and
related conditions, are also reviewed.
1. Introduction
Originally, the term microbiota was intended to describe an ecolo-
gical community of symbionts, commensals, and pathogenic microbes
living within the human body. [1]. The totality of microbiota including
bacteria, fungi, archaea, protists, and viruses colonize the human body
at birth [2,3] where they establish a mutually beneficial host-micro-
biome relationship [1]. This can be seen in specific sites of the human
body including the vagina, gut, skin, and urethra [4]. Gender may be
one of the most important variables that affects microbiota. It has been
reported that there are differences between the number of bacterial
cells ratio with that of human cells in men and women (about 1.3:1 in
men (38 × 1012 and 30 × 1012, respectively) and about 2.2:1 in
women (44 × 1012 and 21 × 1012, respectively) [5]. Sex hormones
have been reported to affect the gut microbiota in adolescence and this
impact is sustained into adulthood. Specific probiotic bacteria are have
been used in the treatments of some cancers in animal models, and it
has been reported that they can reduce tumor proliferation and mod-
ulate inflammation (Fig. 1, A) [6]. However, malignancies are caused
by multiple interactions including hormonal and immune factors;
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Fig. 1. Possible interactions between bacteria and tissues. Diet has a significant effect on the mammary bacteria. Despite the pathogenic effect, the figure also shows
different bacterial profiles in breast tissue that some may be beneficial via their indirect role in breast cancer prevention through the reduction of inflammation and
oxidative stress metabolites (A). The gut microbiota regulates estrogens through secretion of β-glucuronidase. β-glucuronidase de-conjugates estrogen to enable the
binding to estrogen receptors (B). Microbes through might promote cancer by triggering uncontrolled innate and adaptive immune systems via specific epithelial
receptors and penetrate into submucosa layer that can mediate inflammation responses through mediators including cytokines and chemokines (C). Pathways by
which the microbiome could prevent or develop infections as well as carcinogenesis via immune deregulation has shown (D, E).
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furthermore, several groups of cancers are caused by disruption of the
microbial community, which is termed dysbiosis [7,8]. Cancer is one of
the most serious public health issues worldwide. The statistics of new
cancer cases and mortalities in the United States in 2019 caused by
female hormone-sensitive cancers (provided by The National Center for
Health Statistics) has estimated that breast carcinoma is one of the most
common cancers followed by uterine and ovarian cancers [9]. There is a
complex association between cancers and microbes. Despite the fact
that cancers are mainly attributable to genetics and environmental
factors (e.g., diet, alcohol, smoking and radiation), it has been esti-
mated that approximately 2 million new cancer cases were caused by
infections [10,11]. Generally, carcinogenesis can be influenced by
bacteria via four pathways: (I), by stimulating cell proliferation and/or
death, (ii), perturbation immune system function, (iii), impact on the
metabolism within a host cell [11], (iv), genomic stability and DNA
damage [12]. Thus, bacteria can influence the development of cancers
by interacting with the tissue using bacterial components, products and
their metabolism (e.g., estrogens) [13]. The role of the microbiome in
cancer development, as well as estrogen-mediated cancers, will be
considered in this review.
2. Search methods for review
The databases below were searched from the beginning up to March
2020: Embase and MEDLINE through OvidSP, Science Core Collection
website, Scopus database and Google Scholar. To find grey literature,
OpenGrey website was used. Algorithm for electronic search included
terms that refer to the some of the important keywords “Female
cancer”, “Female malignancy” “microbiome” “microbiota” “microbial
communities” “breast dysbiosis” “vaginal dysbiosis” and “uterus dys-
biosis” et cetera. A manual search was used to find reference lists of
related articles and reviews. This manual search was performed to
identify articles not found by the electronic search. In cases where it
was necessary, the authors were contacted to obtain more information.
There was no language restriction for searching or selecting the articles.
3. Functional pathway
3.1. Host cell proliferation and death
Cyclomodulins are a group of bacterial toxins. Cell-cycle progres-
sion can be deregulated by the action of these toxins in the host which
are divided into two groups: stimulatory cyclomodulins (that are cell
proliferation promoters) and inhibitors with their cell-cycle blocking
function [14]. Additionally, human oncoviruses are pathogens that can
trigger a transformation in the cells of the host. They can also lead to
carcinogenesis through the insertion of oncogenes into the genomes; for
example, human papillomaviruses express oncoproteins E6 and E7
[15]. CD97, encoded by the Adhesion G Protein-Coupled Receptor E5
(ADGRE5), is the most commonly expressed member with functions in
cell adhesion, migration, and regulation of intercellular junctions. CD97
is also found in a variety of human cancers, including thyroid, brain,
and gastric cancer [16]. Cell proliferation may be promoted via an
exosome-mediated MAPK-signaling pathway [16]. Also, exosomal
miRNAs are involved in the activation of the CD97-associated pathway
[17,18]. CD97 up regulation is positively correlated with tumor me-
tastasis in hepatocellular carcinoma which may be the result of in-
testinal bacteria [19]. The gut microbiota and toll-like receptors are
able to promote the hepatocellular carcinoma by mediating increased
proliferation. Functionally, CD97 may also promote cell migration
[19,20].
3.2. Immune system
Microbes might promote malignancy by triggering an unregulated
innate and adaptive immune system response [21]. Inflammatory
mediators including cytokines and chemokines have direct effects on a
tumor, and contribute to several hall-marks of cancer [22]. Cancer-as-
sociated microbes may target the Wnt/β-catenin signaling pathway. In
regards to colon cancer, for example, bacteria adhere to the epithelial
cell through FadA adhesion to invade and induce inflammatory re-
sponse and oncogenic, which stimulate the growth of cells. FadA trig-
gers β-catenin activation by binding to E-cadherin of the host cell, so
the inflammatory and oncogenic responses will regulate differently. In
an evolving tumor, pro-inflammatory pathways are involved in the
breach of the mucosal barrier. When the boundaries between the host
cell and microbe collapse, receptor recognition patterns and the sig-
naling cascades may engage. NF-κB and STAT3 signaling regulate the
feed-forward loops of chronic inflammation that are associated with
cancers (Fig. 1, C) [11,23]. There is another mechanism by which the
susceptibility to HIV is enhanced via the breaking down of the epithelial
barrier of the vagina followed by the action of vaginal bacteria. These
bacteria promote pro-inflammatory cytokines secretion during the
epithelial cell response to HIV, which may result in decreased trans-
epithelial resistance (Fig. 1, E) [24].
With regards to the gastrointestinal tract, tight epithelial cell junc-
tions reduce gut inflammation. The tight junctions prevent the entry of
microorganisms and their effect in inflammatory bowel disease (IBD).
Accordingly, Urolithin-A (an anti-inflammatory factor) can provide
protection against colitis by repairing the damaged gut barriers that
may be useful in the treatment of inflammatory disease. One report has
shown that Urolithin-A can be generated from a compound extracted
from pomegranates, known as ellagic acid (EA), by the strain
Bifidobacterium pseudocatenulatum INIA P815 in the gastrointestinal
tract [25].
Carrega et al. [26] have examined the association between micro-
biota and regulation of immunity in cancer. The lactococcus spp. can
maintain the cytotoxic activity of natural killers (NK) to modulate
cellular immunity [26]. Other studies have shown that the host immune
response is the main cofactor in inducing different diseases such as
Helicobacter-related disease. Accordingly, several members of the toll-
like receptors (TLR2 and/or TLR) are involved in the recognition of
Helicobacter in the innate immune system [27]. Moreover, HIV-I risk
can be modified by vaginal bacteria that can alter local inflammation.
The secretion of pro-inflammatory cytokines, such as TNFα, IL-8, IL-1α,
IL-1β, and RANTES is induced by several bacteria including Aerococcus,
Fusobacterium, Gemella, Sneathia, Prevotella, and Mobiluncus by the ac-
tivation of Toll-like receptors. These cytokines appear not be induced
while the epithelial cells of the vagina are cultured with L. crispatus that
is protective against HIV, or other commensals of the vagina [24].
There have been few studies that have studied women with gynecolo-
gical malignancies. One study found that during the study period, fifty-
seven women with HIV were diagnosed with concomittent gynecologic
cancers: 46 % with cervical cancers, 16 % with ovarian cancers, 12 %
with endometrial cancers, and the rest 26 % with other gynecologic
cancer. 52 % women of these were diagnosed with stage I disease, and
47 % with stage II–IV disease (Table 1) (28).
3.3. Metabolic function
In breast cancer, the gut microbiota may influence its pathogenesis
through effects on endogenous estrogens. The parent estrogens and
their metabolites are conjugated and excreted into urine or bile; they
ultimately pass into the distal gut, in which some are deconjugated and
Table 1
Characteristics of HIV infected Gynecologic Cancer Patients.
Cervical (45 %) Ovary (15 %) Uterine (12 %) Total
Stage I (61 %) (11 %) (71 %) (52 %)
Stage II–IV (89 %) (28 %) (47 %)
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influenced by resident microbe through several plausible mechanisms.
Therefore, the association appeared to be stronger for estrogen meta-
bolites than for the parent estrogens. Most of these taxa have been
identified as belonging to the Firmicutes or Bacteroidetes phylum [29].
3.4. DNA damage
Microbes also trigger transformation by disrupting the stability of
genome, cell death resistance, and proliferative signals. To survive in
thir environment, several mechanisms have been used by bacteria to
damage the host DNA; such defensive bacterial factors can contribute to
carcinogenic mutational events [11]. Moreover, some bacterial species
may contribute to chronic inflammatory disease by increasing reactive
oxygen species production that may eventually mediate genotoxicity.
Carcinogenesis can also be modulated by releasing different bacterial
toxins that cause DNA damage. As bacteria cross the epithelial barrier,
they can directly insert the toxins into the cell of the host. Various
bacterial toxins such as Bacillus fragilis, colibactin, and cytolethal cause a
carcinogenic cell responses; specifically against DNA damage [30].
4. Breast cancer
Breast cancer (BC) is the most prevalent cancer among females [31].
The annual rate of female breast cancer mortality is estimated at ap-
proximately 41,760 cases per annum in the United States of America
[9]. Breast cancer has many risk factors. Fewer than 10 % of breast
cancers are attributed to genetic mutations [32]; BRCA1/2 gene mu-
tations are one cause for example [33]. Also, it may also be associated
with environmental, hormonal, and lifestyle factors [32,34]. There is a
common form that shows the essential role of endogenous estrogen in
breast cancer development [35]. It can have an effect through a high
level of estrogen and its metabolic differences [36]. As the estrogen
receptor-beta (ER-beta) has been detected in the oral mucosa and
salivary glands, levels of female sexual hormones influence the com-
position of the microbiota in gut and also oral cavity may cause breast
cancer [37]. Furthermore, it has been shown that some bacterial groups
may be additional environmental factors that are involved in the de-
velopment of a tumor through deregulation of signals/pathways in es-
trogens circulation [38,39]. In general, circulating estrogens are
bioactive. Estradiol and estrone are the main circulating estrogens. The
main estrogen produced during pregnancy is estriol while the most
biologically active estrogen is estradiol in the human body, and is se-
creted by ovarian granulosa cells. Estradiol, estrone, and estriol are
produced in peripheral tissues through aromatization and dehy-
drogenases. During the hepatic phase II metabolism, estrogens are
conjugated by glucuronic acid and sulfate enzymes such as UDP-glu-
curonosyltransferases and sulfotransferases. After the conjugation,
these hormones may be excreted in the feces or urine after becoming
water-soluble or may turn into a lipophilic moiety. Conjugated estro-
gens are excreted into the bile. They can also be found in intestines
[13,35]. So, The gut microbiota is able to regulate estrogens through
secretion of β-glucuronidase [40]. Recent advances have indicated that
the interaction of estrogens and gut microbiota may be associated with
obesity, diabetes, and cancer [41]. Moreover, it has been suggested that
the microbiota of breast cancer patients is different compared to that of
healthy females, demonstrating that certain bacterial communities are
associated with the development of cancer as they are recognized in
carcinogenic tissue [42].
5. Gut microbiome
The human intestine contains approximately 100 trillion gut mi-
crobiota, comprising approximately 500–1000 different species [43].
Gut bacteria have long been considered essential in human health, such
as supplying nutrients, producing vitamin K and vitamin B, digesting
and absorbing indigestible carbohydrates (fibers), and promoting
angiogenesis and enteric nerve function. However, they can potentially
be harmful [44]. Gut microbiota composition in the over 70 s may be
affected by changes in the physiological function of the gut [5]. How-
ever, their symbiotic relationship, termed “normobiosis”, with the host
maintain a balance within the gut. A disruption in the balance, known
as “dysbiosis”, under abnormal conditions is assumed to have deleter-
ious consequences for the host [45]. For instance, several studies ana-
lyzing the association between the gastrointestinal microbiome and
breast cancer [42]. The implication is that breast cancer is associated
with estrogen-dependent functions of the gastrointestinal microbiome
[46]. Many studies are investigating the relationship between breast
cancer and gut microbiome. In 2011, researchers discussed the so-called
“estrobolome” which is known as the gut microbiota gene repertoire,
whose products metabolize estrogen and its metabolites [47]. Estrogens
are deconjugated by gut microbiota via bacterial secretion of β-glu-
curonidase to enable the binding to estrogen receptors (Fig. 1, B) [47];
then, they are reabsorbed as free estrogens and reach tissues like the
breast [42]. The effect of the microbiota is influenced by several factors
such as genetic, epigenetic, and environmental factors such as diet
(Fig. 1, A) [45]. For instance, it has been shown that dietary fiber may
be effective in the composition of gut bacteria and reduce the activity of
intestinal β-glucuronidase, so that the re-absorption of estrogen fol-
lowed by deconjugation process may be reduced [48]. It is worth
mentioning that, according to recent studies in mouse models, in-
hibiting microbial β-glucuronidase does not prevent the breast carci-
nogenesis [49]. Estrogen receptor-positive breast cancer is the most
common subtype of breast cancer [50]. Most effects are mediated via
two estrogen receptors: estrogen receptor alpha (ER-alpha) and beta
(ER-beta). ER is the protein that is expressed in 50–80 % of mammary
tumors, while ER is more abundant in normal human mammary glands.
Breast cancer is classified based on gene expression profiles into four
types: (I), overexpression of human epidermal growth factor receptor 2
(HER2), (ii), Triple-negative carcinoma (TNC) which are negative for
HER2, ER and PR, (iii), Luminal A (ER and PR positive, low prolifera-
tion rate), (iv), Luminal B (ER and PR positive, high proliferation rate)
[51]. The number of cells entering G0 and G1 increases as a result of
estrogen receptor activation and this stimulates proliferation, which
can be identified in breast cancer [52]. A diverse community of mi-
croorganisms colonizes the human gastrointestinal tract [53], so it can
be considered as the best choice to investigate the microbiota and a
model to investigate the interactions between host and microbiota,
which may cause disease. The main genera of gut microbiota are:
Lactobacillus, Bacteroides, Faecalibacterium, Clostridium, Eubacterium,
Ruminococcus, Peptococcus, Peptostreptococcus, Streptococcus, Strepto-
myces and Bifidobacterium. In addition, various studies have suggested
an interaction between gut microbiota and estrogen. Bilateral ovar-
iectomy in humans has been reported to be associated with the higher
abundance of Clostridium bolteae [5]. In men as well as postmenopausal
women (but not in pre-menopausal women), there was a significant
relationship between total urinary estrogen level and richness and α-
diversity of intestinal microbiota [5]. Higher levels of non-ovarian
systemic estrogens was related to the greater fecal Clostridia (consisting
of non-Clostridiales and three genera in the family of Ruminococcaceae).
Furthermore, by sequencing the 16S rRNA, more than 90 % of bacterial
species within the gut were found to be Bacteroidetes and Firmicutes, as
well as Proteobacteria [38,53]. Specifically, many β-glucuronidase
bacteria can be found in two sub-groups that belong to the Firmicutes
phylum, the Clostridium coccoides group, and the Clostridium leptum
group. Also, a member of proteobacteria phylum, the Escherichia/shigella
bacterial group, can possess β-glucuronidase enzymes [54]. Moreover,
according to experiments on feces from 32 breast cancer patients, Bard
and colleagues [55], estimated the absolute numbers of Bifidobacterium
and Blautia, and found that F.Prausnitzii (faecalibacterium genus) and
Blautia were differed in proportion, dependent on the clinical stages of
disease. It has been indicated from staging study that in comparison
with grade I breast cancer patients, women with grade III cancer were
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detected with a higher absolute count of Blautia [55]. In addition,
Goedert et al. [56] studied 19 feceal samples and urine from 48 post-
menopausal women with breast cancer and 48 controlled women. It
was found that the gut microbiota detected from patients with breast
cancer was higher in the level of Clostridiaceae, Faecalibacterium and
Ruminococcaceae (beta diversity) while the levels of Dorea and Lach-
nospiraceae (alpha diversity (P ≤ 0. 004)) which was estrogen- in-
dependent were lower compared to controlled women. Also, a higher
level of systematic estrogen was found in patients. In controls, total
urinary estrogen was correlated with the alpha diversity but not in cases
[56]. Fuhrman et al. [29] studied 60 healthy postmenopausal women
and claimed that women with a more diverse gastrointestinal micro-
biome, particularly four Clostridia taxa, have shown to have a high
proportion of hydroxylated estrogen metabolites to parent estrogens in
the urine. These diff ;erences in results of breast cancer and the di-
versity of gastrointestinal microbiota can prove the effect of the disease
stage on the microbiota [37].
Goedert et al., have reported that the association between the gut
microbiota and breast cancer is related to inflammation that may lead
to IgA production by plasma cells resident in the gut mucosa. By di-
viding cases into those with IgA + and IgA- microbiota, cancer cases
were found to have an altered composition of IgA+, lower richness and
alpha diversity of microbiota in feces. Moreover, estrone, estradiol and
main estrogen metabolites had a lower level in controls via cases. In
comparison with controls, postmenopausal females with BC had a dif-
ferent estrogen-independent relationship with IgA±microbiota, con-
cluding that the gut microbiota affects BC risk through altering the
metabolism, estrogen recycling, and immune pressure [57].
A potential causal role of gut microbiota in the development of
obesity using germ-free animals and microbiota transplant has been
reported [58] and it is known that obesity is associated with a
35%–40% increased risk of BC recurrence and mortality [59]. It has
been reported that BMI is association with the composition of the gut
microbiota including the Firmicutes and Bacteroidetes phyla which were
the most numerous, representing 39.4 % and 13.0 % of total bacteria,
respectively. The Firmicutes phylum combines the subdominant C.
leptum cluster, C. coccoides cluster, F. prausnitzii and R. intestinalis [60].
However, some gut bacteria may reach the mammary glands via an
entero-mammary pathway which involves the translocation of immune
cell-mediated bacteria from the mother's gastrointestinal tract into the
mammary gland [61,62]. It is noteworthy that soy isoflavones, that
have estrogen-like metabolites can structurally alter the composition of
the gut microbial community in postmenopausal women. They do this
by increasing the concentration of bifidobacterium and simultaneously
suppressing the non-classified Clostridiaceae [63]. It is possible to
modulate the gut microbiota by estrogen. However, gut microbiota can
also affect estrogen levels. This is via deconjugation of the conjugated
estrogens excreted in the bile and its reabsorption by enterohepatic
circulation [64]. There is a relationship between increasing serum 25
(OH) D, the the beneficial effects of bacteria and reduced levels of
pathogenic bacteria. After vitamin D supplementation, an increase din
bacteria associated with a decrease in the activity of inflammatory
bowel disease which was dependent on its dose [65]. The environ-
mental bacteria colonization of the gut is associated with im-
munosuppression induced by HIV [66]. Other Studies have shown that
bacterial vaginosis occurs after a shift in Lactobacillus dominance to
non–Lactobacillus-dominant microbiome contains a high population of
Gardnerella vaginalis and anaerobic bacteria, such as Prevotella ssp.,
Mobiluncus ssp.,and/or several Clostridia species which is related with
susceptibility to viral infections and increased HIV infection risk in
women and results in poor reproductive health [67]. Other studies
demonstrate that there is also a relationship between CD4 + T cell
recovery in patients with HIV and gastrointestinal bacterial metabolism
through induction in the alterations of the gut microbiome [68].
However, it has been reported that HIV is not capable of targeting
bacteria. But, it is worth mentioning that antiretroviral drugs which are
used in the HIV infection treatment may affect the gut microbiota.
Antiretroviral drugs decrease the abundance of the pathogenic species
of the gut that may involve in the modification of lipid and glycan, in
order to preserve the colonic cell functions and to be assistance in the
integrity of the cell surface [68]. Gardnerella vaginalis and other anae-
robic bacteria have been evaluated as intervention factors to modify
Tenofovir (Antiretroviral drug) gel microbicide effectiveness by biolo-
gical mechanisms that contribute to increased vaginal inflammation
and adherence [67]. Women with HIV are more vulnerable to gyne-
cological and non-gynecological cancers, and cervical cancer is the
most common cancer in these patients, and they develop invasive cer-
vical cancer five times more frequently than women without HIV [69].
Also, other research has explained that combined antiretroviral therapy
decreased Classical AIDS-defining malignancies and shifted to other
non-AIDS-defining malignancies such as anal, lung, colorectal, and liver
cancers [70].
6. Mammary microbiome
Some researchers have studied the role of the microbes inhabiting
particular human body sites. Xuan et al. [71] observed different levels
ofMethylobacterium and Sphingomonas in the tissue of paired normal or/
and healthy women and women with estrogen receptor (ER)-positive
breast cancer, suggesting their potential relationship in the develop-
ment of cancer. In tumor tissue, Methylobacterium was enriched, while
the absolute levels of bacterium Sphingomonas were higher compared to
paired normal tissue. However by using qPCR, in all samples, the levels
of Methylobacterium between tumor tissue and paired normal (p =
0.2508) were not different. It has been reported that, in tumor tissue, a
higher relative abundance may reflect a decrease in the presence of
other bacteria but the absolute level of the organism does not increase.
In paired normal tissues, a strong correlation between the abundance of
Sphingomonas and Methylobacterium (p = 0.0003) has been reported,
which could not be found in the corresponding tumor tissue. It was also
suggested that, according to paired normal tissue, Sphingomonas and
Methylobacterium are able to provide a counterbalance in abundance
between each other. Meanwhile, the level of Sphingomonas becomes
lower significantly, while the level of Methylobacterium remains steady,
in tumor tissue [71]. In contrast, Wang et al. [72] reported that the
abundance of Methylobacterium was reduced in woman with breast
cancer while at the site of the tumor it was reported to be increased in
the research done by Xuan et al. [71]. On the other hand, using 16S
rRNA sequencing and culture, Urbaniak and colleagues [73] in-
vestigated the mammary tissue microbiome. They analyzed breast
tissue from 81 individuals of two groups of cases and control women
(Canadian and Irish) and collected bacteria from all sites of the breast in
women aged 18–90. The main phylum was Proteobacteria and in gen-
eral, Gammaproteobacteria (5.0 %), Prevotella (5.0 %), Comamonadaceae
(5.7 %), Propionibacterium (5.8 %), Pseudomonas (6.5 %), Staphylococcus
(6.5 %), Enterobacteriaceae (8.3 %), Acinetobacter (10.0 %), Bacillus
(11.4 %), and Enterobacteriaceae (30.8 %), and were in the most
abundant taxa in the Canadian samples. Moreover, in Irish tissue
samples, Pseudomonas (5.3 %), Propionibacterium (10.1 %), Listeria
welshimeri (12.1 %), and Staphylococcus (12.7 %) were mostly de-
tected. However, they detected Escherichia coli with a high level as an
active cancer promoter in BC patients compared with controls. Urba-
niak et al. showed that the profiles of bacteria vary in the breast tissue
of healthy women, compared to those with BC [73,74]. This idea was
similarly suggested by Heiken [75]. Accordingly, malignancy appears
to be related to taxa enrichment of normally present in low abundance,
including the genera Atopobium, Fusobacterium, Gluconacetobacter, Lac-
tobacillus (Fig. 1, A), and Hydrogenophaga. This research confirmed the
distinct existence of breast microbiome and their differences in the
breast tissue in malignancies and benign disease. Also, the abundance
of Micrococcus, Lactococcus, Prevotella, Corynebacterium, and Strep-
tococcus in healthy women, and Bacteroidetes, Staphylococcus,
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Bacillus, Comamondaceae, and Enterobacteriaceae in woman with
Breast cancer which caused DNA damage in vitro [75].
7. Ovarian cancer
Many factors including diet [76], inflammation, family history, age,
and reproductive factors are involved in determining the risk of ovarian
cancer. Cervicovaginal microbiome imbalance has been identified in
women suffering from ovarian cancer [77]. Dysbiosis of the micro-
biome is suggested to be related to pathology issues such as cancers.
Ovarian cancer is one of the most lethal malignancies of the re-
productive system of women; it affects 1 in 70 women and has the
highest mortality rate of the gynecologic cancers. A unique microbiome
signature has been identified that is related to ovarian cancer. The re-
sults of the pan-pathogen array showed a high significance of a distinct
group of viruses, bacteria, fungi and also parasites in ovarian cancer.
They detected specific Bacterial Firmicutes signatures in the cancer
samples including Abiotrophia, Bacillus, Enterococcus, Erysipelothrix,
Geobacillus, Lactobacillus, Lactococcus, Listeria, Pediococcus, Peptoniphilus
and Staphylococcu [78]. Moreover, Nuno et al. [77] calculated the
proportion of lactobacilli species such as Lactobacillus iners, Lactobacillus
crispatus, Lactobacillus jensenii, and Lactobacillus gasseri for each sample,
which are essential for the protective low vaginal pH generation, in the
cervicovaginal microbiota (Fig. 1, D).
It has found that the occurrence of ovarian cancer, and risk factors
of this disease (i.e., BRCA1 germline mutations), were linked with the O
cervicovaginal microbiota community [77]. In addition, studies have
reported several cases of abdominal pathology in which an elevated
serum CA 125 tumor marker may have contributed to the diagnosis of
ovarian carcinoma . Nevertheless, tuberculosis was diagnosed after
taking peritoneal biopsies and specific tuberculostatic treatment could
normalize serum levels of CA 125 [79]. There is another study that
suggests that the presence of Chlamydia trachomatis infection in pa-
tients with epithelial ovarian carcinomas. Multiple mechanisms can
explain the relationship between Chlamydia and cancer development:
(I) production of reactive oxygen species which may trigger DNA da-
mage and increase the risk of oncogenesis may increase; (ii) inhibit
apoptosis by blocking the release of mitochondrial caspase 3 and cy-
tochrome C, which enables infected cells to escape from the attack of
CD8 + killer T-cell and therefore they are less likely to face a normal
cell-death process; (iii) Disruption of the normal cadherin – catenin
junction structure, which leads to increased exposure to other infections
[80].
The associations between the secretory leukocyte protease inhibitor
(SLPI), Human epididymis protein 4 (HE4) and a second vaginal pro-
tease inhibitor, with the types of vaginal communities of bacteria and
with vaginal concentrations of innate immune mediators or proteases
have been evaluated. Accordingly, when Gardnerella vaginalis dom-
inates a vaginal community, the levels of median vaginal HE4, con-
centrations of MMP-8, IL-1, IL-1ra, and Mannose-binding lectin (MBL),
were the highest. The associations between increased levels of pro-
teases, immune mediators, HE4, and high proportions of G vaginalis
suggested that in the female genital tract, bacteria play an indirect role
in pro-inflammatory immune response [81]. Evidence shows that a
chronic disease development may result in inflammatory profiles of
cytokines and chemokines that remain at specific sites. Recent studies
report a possible link between bacterial infection and carcinogenesis. It
has been hypothesized that Toll-like receptors (TLR) may mediate po-
tential signaling pathways leading to inflammation in cancers. Bacterial
products, such as lipopolysaccharide, directly promote the production
of pro-inflammatory cytokines and the upgrade of tumor endurance
from the ovarian cancer cells [82].
Another hypothesis has proposed an association between the mi-
crobial effect on Polycystic Ovarian Syndrome development (PCOS).
Gut microbiota dysbiosis may be caused by poor diet that increases the
permeability of the gut mucosa, resulting in a rise in the movement of
lipopolysaccharide (LPS) from Gram-negative colonic bacteria into the
systemic circulation. The subsequent immune system activation inter-
feres with the function of the insulin receptor, enhancing serum levels
of insulin that in turn increases the production of androgen action in the
ovaries and interferes with the expected development of follicles.
Accordingly, the Dysbiosis of the Gut Microbiota theory of PCOS may
be responsible for the development of multiple small ovarian cysts [83].
As it also introduced among rodents, the gut microbiota composition
was varied from that in the controls. While Clostridium, Ruminococcus,
and Lactobacillus were lower compared to control rats, Prevotella was
higher among PCOS rats [84].
8. Uterine cancer
Uterine cancer is increasing in incidence and attributable mortality
[85]. This cancer can develop via several pathways, including via an
inflammatory response, changes in microbiota, or endocrine disruption
[86]. In particular, changes in intestinal and vaginal microbiomes can
be related with a number of gynecological cancers, including uterine
cancer [87]. Based on the research of Tissier [88], it was concluded that
a healthy uterine cavity is sterile. Multiple reports have questioned this
assumption and it has been shown that the cervical mucus plug is not
completely impermeable to vaginal bacterial ascension [89]. The va-
ginal microbiome consists of a variety of bacterial species between 20
and 140 in particular individuals [90]. Uterine colonization with va-
ginal bacteria was hypothesized to promote carcinogenesis via micro-
biota-mediated pathophysiological change in the microenvironment
[89]. In fact, the microbiome is considered to participate in oncogenesis
by stimulating pro-inflammatory cytokines which are secreted from the
host cells or by mediating dysbiosis-related growth factors [21]. Wal-
ther-António et al. [91] studied the microbiome in samples which were
taken from various sites along the female reproductive tract in women
with endometrial hyperplasia and endometrial cancer and patients who
were afflicted with benign uterine conditions. Accordingly, microbiome
sequencing (16S rDNA) showed that microbiomes of organs, such as the
ovaries, cervix, vagina, and Fallopian tubes, are correlated, and there is
a systemic microbiome change in cases of cancer and hyperplasia,
which can be differentiated from benign cases. In samples that belonged
to endometrial cancer, some taxa have detected to be substantially
enriched including Atopobium vaginae and a Porphyromonas sp. which
are related to disease development, especially in the presence of a
raised level of vaginal pH (> 4.5). Therefore, an increase in vaginal pH
was associated with endometrial cancer [91]. It is worth mentioning
that, Lactobacilli acidify the vagina with lactic acid and may play a role
in the reduced incidence of vaginal bacteria and some reproductive
tract infections (Fig. 1D) [92]. In addition, several types of lactobacilli
may be protective against HIV and the virus is unlikely to develop
women with Lactobacillus-dominant vaginal microbiome [24]. Another
study has claimed that increased vaginal pH is associated with en-
dometriosis and gonadotropin-releasing hormone (GnRH) therapy
suggesting a relationship between the microenvironments of vagina on
proliferative uterine conditions that are hormone-driven [93]. For in-
stance, endometriosis is a diseases process that causes inflammation.
Features of the disease include endometrial lesions growing outside the
uterus that usually affects reproductive age women. It mainly causes
dysmenorrhea and infertility but also causes non-cyclical or chronic
pain of pelvic as well as dyschezia and deep dyspareunia. Evidence
suggests that there is a two-way interaction between endometriosis and
the microbiome that is a complex interaction. It seems that en-
dometriosis is related to the increase of Enterobacteriaceae, proteo-
bacteria, Streptococcus spp. and Escherichia coli in different areas of
microbiome. It also seems that there is an unclear relation between
phylum Firmicutes and the genus Gardnerella [94]. Endometriosis is the
pathophysiology condition in which estrogen-dependent disease [95].
The “strobolum” is inside the gut microbiome that encloses enteric
microbial genes. Products obtained in this process can metabolize
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estrogens in gut [96]. Enteric bacteria secretes β‐glucuronidase and
β‐glucosidases that increases estrogen deconjugation [39,96]. This
process itself increases free estrogen’s reabsorption that lead to higher
levels of circulation. In a microbial genome analysis it was determined
that there are several microbiome-encoded β-glucuronidase in gut mi-
crobiome such as Bifidobacterium, Bacteroides, Escherichia and Lactoba-
cillus [39]. In particular, it was reported that the genus Escherichia
levels were significantly higher in the stools of patients with en-
dometriosis [97]. Recently, it is not clear that what role the estrobolome
and β-glucuronidase-producing bacteria play in endometriosis. But it is
said that a dysbiotic gut microbiome that increases estrogens decon-
jugation followed by increased levels can create an environment with
hyper estrogenic activity that in turn causes the development of en-
dometriosis [94]. The level of Gardnerella, Streptococcus, Escherichia,
Shigella and Ureoplasma (all comprise potentially pathogenic species)
are increased in the cervical microbiota with stage III–IV endometriosis
[97]. There was a greater dominance of Escherichia/Shigella in stool
samples of women in the group of stage III–IV endometriosis [97]. The
relative abundance of gastrointestinal (GI) microbiota can vary over the
lifetime of the host and it is worth to say that, the maternal bacteria that
are obtained during vaginal delivery can influence the disease. Gen-
erally, the gastrointestinal (GI) microbiome has five main bacterial
phyla: Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and Pro-
teobacteria. Such bacteria comprise about 90 % of the total microbiota
in the intestine [98]. On the other hand, members of the Firmicutes
phylum, governed by Lactobacillus iners, Lactobacillus jensenii, Lactoba-
cillus crispatus, and Lactobacillus gasseri inhabit the healthy vagina and
also can change their abundance over the time [99]. Pelvic in-
flammatory disease (PID) occurs when pathogenic bacteria reach the
upper genital tract through the cervix and cause uterine (as well as the
fallopian tubes and ovaries) inflammation [100]. Study results showed
that women with adequate levels of Lactobacilli species and a relative
abundance of Mycoplasma hominis, G. Vaginalis, Ureaplasma urealyticum
(To a lesser degree) and Gram-negative anaerobic bacteria were much
more potential to develop PID [101]. Furthermore, in the upper genital
tract, the chronic inflammatory state caused by PID might cause a
dysfunction in the endothelial cells of uterus. Thus, dysfunction of en-
dothelium and chronic inflammation can cause carcinoma [87]. In
addition, recent studies have suggested that steroid hormones such as
estrogens, and intestinal microbiota may synergize to cause cancer as it
has mentioned before [41]. It is worth noting that estrogens including
the natural hormones estrone and estradiol, induce different types of
tumors in laboratory animals. It is also recognized to be a carcinogen in
humans, raising the risk for uterine cancer as well as breast cancer
which have discussed previously. Different types of DNA damage were
observed as part of the research into the mechanisms of carcinomas
induced by hormones which were mediated by estrogen in cell-free
systems, in vivo or in cultured cells [102]. There is a relationship be-
tween pelvic inflammatory disease and vaginal microbiome and bac-
terial vaginosis. Thus, microbiome disruption can be considered as an
indirect risk factor for endometrial cancer. Similarly, ovarian cancer
risk can be improved through the indirect effects of the vaginal mi-
crobiome, modulation of local immunosurveillance and regional in-
flammation. Recently, one study showed that the ovaries and fallopian
tubes have a specific microbiome. Compared to the control group
without cancer, there were different compositions of microbiomes of
upper genital tract in patients with epithelial ovarian cancer. There was
also a relationship between the composition of the uterine microbiome
and endometrial cancer in a new study. Especially there was a re-
lationship between cancer, A. vaginae and a Porphyromonas species
[90]. The role in oncogenesis is not only limited to bacteria but ac-
cording to the study of Mileshkin et al. [103], the incidence of cervical
cancer among women with HIV is growing. In fact, there is an asso-
ciation between enhanced HPV uterine cervical carcinogenesis and
immunosuppression followed by HIV [104]. Microbiomes with high
levels of L. crispatus were generally related to healthy individuals [105].
On the other hand, Lactobacillus iners was related to cervical cancer
alone [106] or in combination with HPV infection and a higher degree
of cervical intraepithelial neoplasia (CIN) in patients with a positive
HPV test [107]. Atopobium vaginae, Gardnerella vaginalis, and Lacto-
bacillus iners may cause the synergistic effect of the risky microbial
pattern with HPV infection on the increase of cervical intraepithelial
neoplasia risk [107] (Table 2). However, another study showed that
there was a relationship between L. iners and reduction of squamous
intraepithelial lesions risk and cervical cancer [105]. Cervical in-
traepithelial neoplasia (CIN) was also related to other Lactobacillus
species in a variable manner. Also there was a relationship between CIN
and less abundant bacterial species (Atopobium vaginae, G. vaginalis,
Fusobacterium, etc.) [90]. Cytokine profiling has indicated increased
interleukin (IL)‐4 and TGF-βRI mRNA local levels in Fusobacterium-
dominated gut microbiomes (Fig. 1, E) [90]. In a similar way, in in
patients with squamous intraepithelial lesion microbiomes with high
levels of Sneathia were observed (Table 2). Diet has a potential impact
on the microbiome. A higher rate of CIN observed in women with
semi‐Western‐style diets compared with fish and vegetables rich diets
[90]. Moreover, the sex-hormone-the microbiome-immune system will
affect women's susceptibility to HIV-1. Serious shifts of hormones can
change the proportion of anaerobic bacteria to those influenced by
lactobacilli. If the levels of estrogen decrease significantly in meno-
pausal women, lactobacilli become less likely in dominating the vaginal
microbiome [24].
9. New clinical trials
The ClinicalTrials.gov Web site, is a study database for breast, ovary
and endometrium conditions or diseases, a summary of the study pro-
tocol, including the purpose of study, status, the number of participants,
and outcome measures is shown in (Table 3).
10. Conclusion
Some bacteria are known to affect human health including organ-
isms that are associated with breast, ovarian, and uterine cancers. In
regards to cancer development, bacteria are considered to have an
important pathogenic role in carcinogenesis through several different
mechanism. Additionally, specific bacteria and/or viruses are described
as cancer-inducing factors in this review. Despite their potential onco-
genic effects, microbiota might be manipulated for the treatment of
cancers, so information about the role of the bacteria in cancers re-
quires further investigations. Some female cancers are also diagnosed
among HIV-infected individuals which are possible to be associated
with the most common sexually transmitted infectious agent, human
papillomavirus (HPV) and considered to be a new target to study. Even
the link between HIV -or other viruses- and carcinogens via im-





Association of different vaginal microbiome species with disease development.
Bacteria Association with HPV Association with CIN
Lactobacillus iners – +
Lactobacillus gasseri + –
Atopobium vaginae + +
Gardnerella vaginalis + +
Fusobacterium + +
Sneathia + +





[1] S. Sirisinha, The potential impact of gut microbiota on your health: current status
and future challenges, Asian Pac. J. Allergy Immunol. 34 (4) (2016) 249–264.
[2] M.C. Arrieta, L.T. Stiemsma, N. Amenyogbe, E.M. Brown, B. Finlay, The intestinal
microbiome in early life: health and disease, Front. Immunol. 5 (2014) 427.
[3] K. Schlaeppi, D. Bulgarelli, The plant microbiome at work, Mol. Plant Microbe
Interact. 28 (3) (2015) 212–217.
[4] B. Vicinus, C. Rubie, S.K. Faust, V.O. Frick, P. Ghadjar, M. Wagner, et al., miR-21
functionally interacts with the 3’UTR of chemokine CCL20 and down-regulates
CCL20 expression in miR-21 transfected colorectal cancer cells, Cancer Lett. 316
(1) (2012) 105–112.
[5] Y.S. Kim, T. Unno, B.-Y. Kim, M.-S. Park, Sex differences in gut microbiota, World
J. Mens Health 38 (1) (2020) 48–60.
[6] A.A. Hibberd, A. Lyra, A.C. Ouwehand, P. Rolny, H. Lindegren, L. Cedgård, et al.,
Intestinal microbiota is altered in patients with colon cancer and modified by
probiotic intervention, BMJ Open Gastroenterol. 4 (1) (2017) e000145.
[7] J. Yang, Q. Tan, Q. Fu, Y. Zhou, Y. Hu, S. Tang, et al., Gastrointestinal microbiome
and breast cancer: correlations, mechanisms and potential clinical implications,
Breast Cancer 24 (2) (2017) 220–228.
[8] G.A. Weiss, T. Hennet, Mechanisms and consequences of intestinal dysbiosis, Cell.
Mol. Life Sci. 74 (16) (2017) 2959–2977.
[9] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA Cancer J. Clin. 69 (1)
(2019) 7–34.
[10] F.P. Perera, Environment and cancer: who are susceptible? Science 278 (5340)
(1997) 1068–1073.
[11] W.S. Garrett, Cancer and the microbiota, Science 348 (6230) (2015) 80–86.
[12] V.J. Koller, B. Marian, R. Stidl, A. Nersesyan, H. Winter, T. Simić, et al., Impact of
lactic acid bacteria on oxidative DNA damage in human derived colon cells, Food
Chem. Toxicol. 46 (4) (2008) 1221–1229.
[13] S. Mani, Microbiota and breast cancer, Prog. Mol. Biol. Transl. Sci. 151 (2017)
217–229.
[14] E. Oswald, J.-P. Nougayrède, F. Taieb, M. Sugai, Bacterial toxins that modulate
host cell-cycle progression, Curr. Opin. Microbiol. 8 (1) (2005) 83–91.
[15] A.I. Ojesina, L. Lichtenstein, S.S. Freeman, C.S. Pedamallu, I. Imaz-Rosshandler,
T.J. Pugh, et al., Landscape of genomic alterations in cervical carcinomas, Nature
506 (7488) (2014) 371–375.
[16] R. Nedaeinia, M. Manian, M. Jazayeri, M. Ranjbar, R. Salehi, M. Sharifi, et al.,
Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal
cancer, Cancer Gene Ther. 24 (2) (2017) 48–56.
[17] M. Safaee, A.J. Clark, M.E. Ivan, M.C. Oh, O. Bloch, M.Z. Sun, et al., CD97 is a
multifunctional leukocyte receptor with distinct roles in human cancers, Int. J.
Oncol. 43 (5) (2013) 1343–1350.
[18] R. Nedaeinia, M. Manian, M.H. Jazayeri, M. Ranjbar, R. Salehi, M. Sharifi, et al.,
Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal
cancer, Cancer Gene Ther. 24 (2) (2017) 48–56.
[19] Y. Yin, X. Xu, J. Tang, W. Zhang, G. Zhangyuan, J. Ji, et al., CD97 promotes tumor
aggressiveness through the traditional g protein–Coupled receptor–Mediated sig-
naling in hepatocellular carcinoma, Hepatology 68 (5) (2018) 1865–1878.
[20] H. Dapito Dianne, A. Mencin, G.-Y. Gwak, J.-P. Pradere, M.-K. Jang, I. Mederacke,
et al., Promotion of hepatocellular carcinoma by the intestinal microbiota and
TLR4, Cancer Cell 21 (4) (2012) 504–516.
[21] C. Jobin, The microbiome and cancer, Nat. Rev. Cancer 13 (2013) 800–812.
[22] S.M. Crusz, F.R. Balkwill, Inflammation and cancer: advances and new agents, Nat.
Rev. Clin. Oncol. 12 (10) (2015) 584–596.
[23] R. Rubinstein Mara, X. Wang, W. Liu, Y. Hao, G. Cai, W. Han Yiping,
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-
cadherin/β-catenin signaling via its FadA adhesin, Cell Host Microbe 14 (2)
(2013) 195–206.
[24] J.M. Wessels, A.M. Felker, H.A. Dupont, C. Kaushic, The relationship between sex
hormones, the vaginal microbiome and immunity in HIV-1 susceptibility in
women, Dis. Model. Mech. 11 (9) (2018) dmm035147.
[25] R. Singh, S. Chandrashekharappa, S.R. Bodduluri, B.V. Baby, B. Hegde, N.G. Kotla,
et al., Enhancement of the gut barrier integrity by a microbial metabolite through
the Nrf2 pathway, Nat. Commun. 10 (1) (2019) 89.
[26] P. Carrega, I. Bonaccorsi, E. Di Carlo, B. Morandi, P. Paul, V. Rizzello, et al., CD56
bright perforin low noncytotoxic human NK cells are abundant in both healthy and
neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent
lymph, J. Immunol. 192 (8) (2014) 3805–3815.
[27] C. Stoicov, R. Saffari, X. Cai, C. Hasyagar, J. Houghton, Molecular biology of
gastric cancer: helicobacter infection and gastric adenocarcinoma: bacterial and
host factors responsible for altered growth signaling, Gene 341 (2004) 1–17.
[28] K.L. Levinson, D.J. Riedel, L.S. Ojalvo, W. Chan, A.M. Angarita, A.N. Fader, et al.,
Gynecologic cancer in HIV infected women: treatment and outcomes in a multi-
institutional cohort, AIDS (London, England) 32 (2) (2018) 171.
[29] B.J. Fuhrman, H.S. Feigelson, R. Flores, M.H. Gail, X. Xu, J. Ravel, et al.,
Associations of the fecal microbiome with urinary estrogens and estrogen meta-
bolites in postmenopausal women, J. Clin. Endocrinol. Metab. 99 (12) (2014)
4632–4640.



















































































































































































































































































































































































































































































































































































































































































































































































































































N. Alizadehmohajer, et al. Biomedicine & Pharmacotherapy 127 (2020) 110203
8
cancer development and treatment, J. Cancer Res. Clin. Oncol. 145 (1) (2019)
49–63.
[31] Z. Anastasiadi, G.D. Lianos, E. Ignatiadou, H.V. Harissis, M. Mitsis, Breast cancer
in young women: an overview, Updates Surg. 69 (3) (2017) 313–317.
[32] K. Rojas, A. Stuckey, Breast cancer epidemiology and risk factors, Clin. Obstet.
Gynecol. 59 (4) (2016) 651–672.
[33] P. Murthy, F. Muggia, Women’s cancers: how the discovery of BRCA genes is
driving current concepts of cancer biology and therapeutics,
Ecancermedicalscience 13 (2019) 904.
[34] L. Bernstein, R.K. Ross, Endogenous hormones and breast cancer risk, Epidemiol.
Rev. 15 (1) (1993) 48–65.
[35] H. Samavat, M.S. Kurzer, Estrogen metabolism and breast cancer, Cancer Lett. 356
(2 Pt A) (2015) 231–243.
[36] J.N. Sampson, R.T. Falk, C. Schairer, S.C. Moore, B.J. Fuhrman, C.M. Dallal, et al.,
Association of estrogen metabolism with breast cancer risk in different cohorts of
postmenopausal women, Cancer Res. 77 (4) (2017) 918–925.
[37] A.T. Vieira, P.M. Castelo, D.A. Ribeiro, C.M. Ferreira, Influence of oral and gut
microbiota in the health of menopausal women, Front. Microbiol. 8 (1884) (2017).
[38] D. Rea, G. Coppola, G. Palma, A. Barbieri, A. Luciano, P. Del Prete, et al.,
Microbiota effects on cancer: from risks to therapies, Oncotarget 9 (25) (2018)
17915–17927.
[39] M. Kwa, C.S. Plottel, M.J. Blaser, S. Adams, The intestinal microbiome and es-
trogen receptor–positive female breast cancer, JNCI J. Natl. Cancer Inst. 108 (8)
(2016).
[40] J.M. Baker, L. Al-Nakkash, M.M. Herbst-Kralovetz, Estrogen–gut microbiome axis:
physiological and clinical implications, Maturitas 103 (2017) 45–53.
[41] K.L. Chen, Z. Madak-Erdogan, Estrogen and microbiota crosstalk: should we pay
attention? Trends Endocrinol. Metab. 27 (11) (2016) 752–755.
[42] M.F. Fernandez, I. Reina-Perez, J.M. Astorga, A. Rodriguez-Carrillo, J. Plaza-Diaz,
L. Fontana, Breast cancer and its relationship with the microbiota, Int. J. Environ.
Res. Public Health 15 (8) (2018).
[43] Microbiome and cancer, in: N. Ohtani (Ed.), Seminars in Immunopathology;
Springer, 2015.
[44] Y.-J. Zhang, S. Li, R.-Y. Gan, T. Zhou, D.-P. Xu, H.-B. Li, Impacts of gut bacteria on
human health and diseases, Int. J. Mol. Sci. 16 (4) (2015) 7493–7519.
[45] T.O. Keku, S. Dulal, A. Deveaux, B. Jovov, X. Han, The gastrointestinal microbiota
and colorectal cancer, Am. J. Physiol. Gastrointestinal Liver Physiol. 308 (5)
(2015) G351–G363.
[46] A.N. Chamseddine, M. Ducreux, J.P. Armand, X. Paoletti, T. Satar, A. Paci, et al.,
Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of ir-
inotecan-induced diarrhea severity, Pharmacol. Ther. 199 (2019) 1–15.
[47] C.S. Plottel, M.J. Blaser, Microbiome and malignancy, Cell Host Microbe 10 (4)
(2011) 324–335.
[48] H. Adlercreutz, Western diet and Western diseases: some hormonal and bio-
chemical mechanisms and associations, Scand. J. Clin. Lab. Invest. 50 (Suppl. 201)
(1990) 3–23.
[49] A.P. Beck, H. Li, S.M. Ervin, M.R. Redinbo, S. Mani, Inhibition of microbial beta-
glucuronidase does not prevent breast carcinogenesis in the polyoma middle t
mouse, bioRxiv (2019) 746602.
[50] T. Reinert, E.D. Saad, C.H. Barrios, J. Bines, Clinical implications of ESR1 muta-
tions in hormone receptor-positive advanced breast cancer, Front. Oncol. 7 (26)
(2017).
[51] B. Huang, M. Warner, J.A. Gustafsson, Estrogen receptors in breast carcinogenesis
and endocrine therapy, Mol. Cell. Endocrinol. 418 Pt 3 (2015) 240–244.
[52] S.F. Doisneau-Sixou, C.M. Sergio, J.S. Carroll, R. Hui, E.A. Musgrove,
R.L. Sutherland, Estrogen and antiestrogen regulation of cell cycle progression in
breast cancer cells, Endocr Relat Cancer 10 (2) (2003) 179.
[53] S. Selber-Hnatiw, B. Rukundo, M. Ahmadi, H. Akoubi, H. Al-Bizri, A.F. Aliu, et al.,
Human gut microbiota: toward an ecology of disease, Front. Microbiol. 8 (1265)
(2017).
[54] M. Dabek, S.I. McCrae, V.J. Stevens, S.H. Duncan, P. Louis, Distribution of β-
glucosidase and β-glucuronidase activity and of β-glucuronidase gene gus in
human colonic bacteria, FEMS Microbiol. Ecol. 66 (3) (2008) 487–495.
[55] J.-M. Bard, H.T. Luu, F. Dravet, C. Michel, T. Moyon, A. Pagniez, et al.,
Relationship between intestinal microbiota and clinical characteristics of patients
with early stage breast cancer, FASEB J. 29 (1_supplement) (2015) 914.2.
[56] J.J. Goedert, G. Jones, X. Hua, X. Xu, G. Yu, R. Flores, et al., Investigation of the
association between the fecal microbiota and breast cancer in postmenopausal
women: a population-based case-control pilot study, JNCI J. Natl. Cancer Inst. 107
(8) (2015).
[57] J.J. Goedert, X. Hua, A. Bielecka, I. Okayasu, G.L. Milne, G.S. Jones, et al.,
Postmenopausal breast cancer and oestrogen associations with the IgA-coated and
IgA-noncoated faecal microbiota, Br. J. Cancer 118 (4) (2018) 471.
[58] P. Gérard, Gut microbiota and obesity, Cell. Mol. Life Sci. 73 (1) (2016) 147–162.
[59] S. Jiralerspong, P.J. Goodwin, Obesity and breast cancer prognosis: evidence,
challenges, and opportunities, J. Clin. Oncol. 34 (35) (2016) 4203–4216.
[60] T.H. Luu, C. Michel, J.-M. Bard, F. Dravet, H. Nazih, C. Bobin-Dubigeon, Intestinal
proportion of Blautia sp. Is associated with clinical stage and histoprognostic grade
in patients with early-stage breast cancer, Nutr. Cancer 69 (2) (2017) 267–275.
[61] T. Jost, C. Lacroix, C.P. Braegger, F. Rochat, C. Chassard, Vertical mother–neonate
transfer of maternal gut bacteria via breastfeeding, Environ. Microbiol. 16 (9)
(2014) 2891–2904.
[62] S. Moossavi, M.B. Azad, Origins of human milk microbiota: new evidence and
arising questions, Gut Microbes (2019) 1–10.
[63] C.H. Nakatsu, A. Armstrong, A.P. Clavijo, B.R. Martin, S. Barnes, C.M. Weaver,
Fecal bacterial community changes associated with isoflavone metabolites in
postmenopausal women after soy bar consumption, PLoS One 9 (10) (2014)
e108924.
[64] R. Flores, J. Shi, B. Fuhrman, X. Xu, T.D. Veenstra, M.H. Gail, et al., Fecal mi-
crobial determinants of fecal and systemic estrogens and estrogen metabolites: a
cross-sectional study, J. Transl. Med. 10 (2012) 253.
[65] N. Charoenngam, A. Shirvani, T.A. Kalajian, A. Song, M.F. Holick, The effect of
various doses of oral vitamin D3 supplementation on gut microbiota in healthy
adults: a randomized, double-blinded, dose-response study, Anticancer Res. 40 (1)
(2020) 551–556.
[66] L. Yang, M.A. Poles, G.S. Fisch, Y. Ma, C. Nossa, J.A. Phelan, et al., HIV-induced
immunosuppression is associated with colonization of the proximal gut by en-
vironmental bacteria, AIDS (London, England) 30 (1) (2016) 19.
[67] N.R. Klatt, R. Cheu, K. Birse, A.S. Zevin, M. Perner, L. Noël-Romas, et al., Vaginal
bacteria modify HIV tenofovir microbicide efficacy in African women, Science 356
(6341) (2017) 938–945.
[68] S. Serrano-Villar, D. Rojo, M. Martínez-Martínez, S. Deusch, J.F. Vázquez-
Castellanos, R. Bargiela, et al., Gut bacteria metabolism impacts immune recovery
in HIV-infected individuals, EBioMedicine 8 (2016) 203–216.
[69] A. Subramaniam, J.M. Fauci, K.E. Schneider, J.M. Whitworth, B.K. Erickson,
K. Kim, et al., Invasive cervical cancer and screening: what are the rates of
unscreened and underscreened women in the modern era? J. Low Genit. Tract Dis.
15 (2) (2011) 110.
[70] N.T. Oliver, E.Y. Chiao, Malignancies in women with HIV infection, Curr. Opin.
HIV AIDS 12 (1) (2017) 69.
[71] C. Xuan, J.M. Shamonki, A. Chung, M.L. DiNome, M. Chung, P.A. Sieling, et al.,
Microbial dysbiosis is associated with human breast cancer, PLoS One 9 (1) (2014)
e83744.
[72] H. Wang, J. Altemus, F. Niazi, H. Green, B.C. Calhoun, C. Sturgis, et al., Breast
tissue, oral and urinary microbiomes in breast cancer, Oncotarget 8 (50) (2017)
88122.
[73] C. Urbaniak, J. Cummins, M. Brackstone, J.M. Macklaim, G.B. Gloor, C.K. Baban,
et al., Microbiota of human breast tissue, Appl. Environ. Microbiol. 80 (10) (2014)
3007–3014.
[74] C. Urbaniak, G.B. Gloor, M. Brackstone, L. Scott, M. Tangney, G. Reid, The mi-
crobiota of breast tissue and its association with breast cancer, Appl. Environ.
Microbiol. 82 (16) (2016) 5039–5048.
[75] T.J. Hieken, J. Chen, T.L. Hoskin, M. Walther-Antonio, S. Johnson, S. Ramaker,
et al., The microbiome of aseptically collected human breast tissue in benign and
malignant disease, Sci. Rep. 6 (2016) 30751.
[76] X.O. Shu, Y.T. Gao, J.M. Yuan, R.G. Ziegler, L.A. Brinton, Dietary factors and
epithelial ovarian cancer, Br. J. Cancer 59 (1) (1989) 92–96.
[77] N.R. Nené, D. Reisel, A. Leimbach, D. Franchi, A. Jones, I. Evans, et al., Association
between the cervicovaginal microbiome, BRCA1 mutation status, and risk of
ovarian cancer: a case-control study, Lancet Oncol. 20 (8) (2019) 1171–1182.
[78] S. Banerjee, T. Tian, Z. Wei, N. Shih, M.D. Feldman, J.C. Alwine, et al., The ovarian
cancer oncobiome, Oncotarget 8 (22) (2017) 36225–36245.
[79] F.N. De Paz, B.H. Fernández, R.P. Simón, E.F. Pérez, C.N. De Paz, P.O. Battle, et al.,
Pelvic-peritoneal tuberculosis simulating ovarian carcinoma: report of three cases
with elevation of the CA 125, Am. J. Gastroenterol. 91 (8) (1996).
[80] S. Shanmughapriya, G. SenthilKumar, K. Vinodhini, B.C. Das, N. Vasanthi,
K. Natarajaseenivasan, Viral and bacterial aetiologies of epithelial ovarian cancer,
Eur. J. Clin. Microbiol. Infect. Dis. 31 (9) (2012) 2311–2317.
[81] T. Orfanelli, A. Jayaram, G. Doulaveris, L.J. Forney, W.J. Ledger, S.S. Witkin,
Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal
fluid: relation to vaginal components and bacterial composition, Reprod. Sci. 21
(4) (2014) 538–542.
[82] M.G. Kelly, A.B. Alvero, R. Chen, D.-A. Silasi, V.M. Abrahams, S. Chan, et al., TLR-
4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian
cancer, Cancer Res. 66 (7) (2006) 3859–3868.
[83] K. Tremellen, K. Pearce, Dysbiosis of gut microbiota (DOGMA) – a novel theory for
the development of polycystic ovarian syndrome, Med. Hypotheses 79 (1) (2012)
104–112.
[84] Y. Guo, Y. Qi, X. Yang, L. Zhao, S. Wen, Y. Liu, et al., Association between poly-
cystic ovary syndrome and gut microbiota, PLoS One 11 (4) (2016) e0153196.
[85] S.J. Henley, J.W. Miller, N.F. Dowling, V.B. Benard, L.C. Richardson, Uterine
cancer incidence and mortality - United States, 1999-2016, MMWR Morb. Mortal.
Wkly. Rep. 67 (48) (2018) 1333–1338.
[86] K.M. O’Brien, A.A. D’Aloisio, M. Shi, J.D. Murphy, D.P. Sandler, C.R. Weinberg,
Perineal talc use, douching, and the risk of uterine cancer, Epidemiology 30 (6)
(2019) 845–852.
[87] D. Chase, A. Goulder, F. Zenhausern, B. Monk, M. Herbst-Kralovetz, The vaginal
and gastrointestinal microbiomes in gynecologic cancers: a review of applications
in etiology, symptoms and treatment, Gynecol. Oncol. 138 (1) (2015) 190–200.
[88] J.R. Clamp, L. Hough, J.L. Hickson, R.L. Whistler, Lactose, Advances in
Carbohydrate Chemistry 16 Elsevier, 1962, pp. 159–206.
[89] J.M. Baker, D.M. Chase, M.M. Herbst-Kralovetz, Uterine microbiota: residents,
tourists, or invaders? Front. Immunol. 9 (2018) 208.
[90] M. Champer, A. Wong, J. Champer, I. Brito, P. Messer, J. Hou, et al., The role of
the vaginal microbiome in gynaecological cancer, BJOG Int. J. Obstet. Gynaecol.
125 (3) (2018) 309–315.
[91] Chen J. Walther-António MRS, F. Multinu, A. Hokenstad, T.J. Distad, E.H. Cheek,
et al., Potential contribution of the uterine microbiome in the development of
endometrial cancer, Genome Med. 8 (1) (2016) 122.
[92] D.E. O’Hanlon, T.R. Moench, R.A. Cone, Vaginal pH and microbicidal lactic acid
when lactobacilli dominate the microbiota, PLoS One 8 (11) (2013) e80074.
[93] K.N. Khan, A. Fujishita, M. Kitajima, K. Hiraki, M. Nakashima, H. Masuzaki, Intra-
N. Alizadehmohajer, et al. Biomedicine & Pharmacotherapy 127 (2020) 110203
9
uterine microbial colonization and occurrence of endometritis in women with
endometriosis, Hum. Reprod. 29 (11) (2014) 2446–2456.
[94] M. Leonardi, C. Hicks, F. El-Assaad, E. El-Omar, G. Condous, Endometriosis and
the microbiome: a systematic review, BJOG Int. J. Obstet. Gynaecol. 127 (2)
(2020) 239–249.
[95] J. Kitawaki, N. Kado, H. Ishihara, H. Koshiba, Y. Kitaoka, H. Honjo, Endometriosis:
the pathophysiology as an estrogen-dependent disease, J. Steroid Biochem. Mol.
Biol. 83 (1) (2002) 149–155.
[96] C.S. Plottel, M.J. Blaser, Microbiome and malignancy, Cell Host Microbe 10 (4)
(2011) 324–335.
[97] B. Ata, S. Yildiz, E. Turkgeldi, V.P. Brocal, E.C. Dinleyici, A. Moya, et al., The
endobiota study: comparison of vaginal, cervical and gut microbiota between
women with stage 3/4 endometriosis and healthy controls, Sci. Rep. 9 (1) (2019)
2204.
[98] M. Kosiewicz, A. Zirnheld, P. Alard, Gut microbiota, immunity, and disease: a
complex relationship, Front. Microbiol. 2 (180) (2011).
[99] J. Ravel, P. Gajer, Z. Abdo, G. Schneider, S. Koenig, Vaginal microbiome of re-
productive-age women, Proc. Natl. Acad. Sci. U. S. A. 108 (Suppl 1) (2011)
4680–4687, https://doi.org/10.1073/pnas.1002611107.
[100] H. Sharma, R. Tal, N.A. Clark, J.H. Segars, Microbiota and pelvic inflammatory
disease, Semin. Reprod. Med. 32 (2014) 043–049, https://doi.org/10.1055/s-
0033-1361822.
[101] R.B. Ness, K.E. Kip, S.L. Hillier, D.E. Soper, C.A. Stamm, R.L. Sweet, et al., A cluster
analysis of bacterial vaginosis–associated microflora and pelvic inflammatory
disease, Am. J. Epidemiol. 162 (6) (2005) 585–590.
[102] J.G. Liehr, Genotoxicity of the steroidal oestrogens oestrone and oestradiol: pos-
sible mechanism of uterine and mammary cancer development, APMIS 109 (S103)
(2001) S519–S527.
[103] L. Mileshkin, E. Ponnusamy, C.L. Cherry, Uterine Cervical Cancer in Women with
HIV Infection. Uterine Cervical Cancer, Springer, 2019, pp. 89–105.
[104] L. Mileshkin, E. Ponnusamy, C.L. Cherry, Uterine cervical cancer in women with
HIV infection, in: S.A. Farghaly (Ed.), Uterine Cervical Cancer: Clinical and
Therapeutic Perspectives, Springer International Publishing, Cham, 2019, pp.
89–105.
[105] A. Audirac-Chalifour, K. Torres-Poveda, M. Bahena-Román, J. Téllez-Sosa,
J. Martínez-Barnetche, B. Cortina-Ceballos, et al., Cervical microbiome and cyto-
kine profile at various stages of cervical cancer: a pilot study, PLoS One 11 (4)
(2016) e0153274-e.
[106] S.-S. Seo, H.Y. Oh, J.-K. Lee, J.-S. Kong, D.-O. Lee, M.K. Kim, Combined effect of
diet and cervical microbiome on the risk of cervical intraepithelial neoplasia, Clin.
Nutr. 35 (6) (2016) 1434–1441.
[107] H.Y. Oh, B.S. Kim, S.S. Seo, J.S. Kong, J.K. Lee, S.Y. Park, et al., The association of
uterine cervical microbiota with an increased risk for cervical intraepithelial
neoplasia in Korea, Clin. Microbiol. Infect. 21 (7) (2015) 674.e1–.e9.
N. Alizadehmohajer, et al. Biomedicine & Pharmacotherapy 127 (2020) 110203
10
